Table 1.
Studies involving the use of electrospun fibers in drug delivery (partial listing).
| Drug(s) | Polymer(s) | Solvent Composition | Spraying Type |
|---|---|---|---|
| Antibacterial agents | |||
| Tetracycline hydrochloride | PEUU and PLGA [71]; PLA, PEV, PLA/PEVA [113]; PLA/PCL [132] PLLA [133,134]; PCL, PEVA [114] |
1,1,1,3,3,3-Hexafluoro-2-propanol [71]; Chloroform [113]; Chloroform, dimethylformamide [132]; Chloroform: acetone (2:1) [133,134]; chloroform:methanol (9:1) [114] |
Single nozzle; Coaxial [133,134] |
| Gentamycin sulfate and Resveratrol (antioxidant) | PCL [133] | Chloroform: ethanol (3:1) | Coaxial |
| Ciprofloxacin Hydrochloride | PVA, Poly(vinyl acetate) [84] | Diluted acetic acid solution | Single nozzle |
| Fusidic acid and rifampicin | PLGA [135] | Tetrahydro Furan/Dimethylformamide | Single nozzle |
| Mefoxin | PLGA [83] | DMF | Single nozzle |
| Metronidazole benzoate | PCL [136] | Dichloromethane (DCM:DMF) | Single nozzle |
| Ciprofloxacin hydrochloride, Levofloxacin hemihydrate, Moxifloxacin hydrochloride |
coPLA, coPLA/PEG [137] | DCM:DMSO (3:1) | Single nozzle |
| Lidocaine and mupirocin | PLLA [120] | Hexafluoroisopropanol | Dual spinneret |
| Ornidazole (Biteral®) | PCL | Chloroform and DMF (3:7) | Single nozzle |
| Potassium 5-nitro-8-quinolinolate | Chitosan/PEO [138] | 2% (w/v) acetic acid | Single nozzle |
| Itraconazole and ketanserin | PU [139] | DMF, DMAc | Single nozzle |
| Pleurocidin | PVA [116] | Distilled water | Single nozzle |
| NSAIDS | |||
| Ketoprofen | PVA/PAA/MWCNT [92]; PEO/PETA/MWCNT [109]; EC and PVP [140]; PVP/Zein [141] | Deionized water [92,109] Ethanol-water [140,141] |
Single nozzle Coaxial [141] |
| Ibuprofen | PLGA PEG-g-CHN [142] | DMF | Side-by-side |
| Fenbufen | PLGA/Gelatin [82] | 2,2,2-trifluoroethanol | Single nozzle |
| Rhodamine B/Naproxen | Chitosan nanoparticles/PCL composite [100] | Acetic acid/chloroform: methanol (3:1) | Single nozzle yet core/sheath fiber |
| Meloxicam | PVA [111] | Water | Single nozzle |
| Anticancer agents | |||
| Doxorubicin [127] Doxorubicin Hydrochloride |
PLLA [127] PEG-PLA [124,143] |
Chloroform-methano-DMSO [127] Chloroform [143] w/o emulsion [124] |
Single nozzle Emulsion [124] |
| Hydroxycamptothecin | HPCD [128] | DMSO | Emulsion |
| Paclitaxel | Chitosan/PEO/HA [84] PLGA [144,145] |
Acetic acid/distilled water [84] DCM and DMF |
Single nozzle |
| Cisplatin | PLA/PLGA [126] | DCM | Single nozzle |
| Dichloroacetate | PLA [146] | Chloroform | Single nozzle |
| 1,3-Bis(2-chloroethyl)-1-nitrosourea | PEO and PEG-PLLA [147] | Chloroform | Single nozzle/Emulsion |
| Curcumin | Cellulose acetate [108] | Acetone/dimethylacetamide (2:1) | Single nozzle |
| Green tea polyphenols (GTP) | PCL/MWCNT [131] | Dichloromethane | Single nozzle |
| Titanocene dichloride | PLLA [130] | Dichloromethane | Single nozzle |
PLA: Poly(lactic acid); PEVA-Poly(ethylene-co-vinylacetate); PCL: poly(ε-caprolactone); PCL-co-PCLEEP: Copolymer of caprolactone and ethyl ethylene phosphate; PLGA: Poly(d,l-Lactic acid-co-glycolic acid); PEUU: poly(ester urethane) urea; EC: ethyl cellulose; PEO: Poly(ethylene oxide); PU: Polyurethane; DMAc: Dimethylacetamide; PETA: pentaerythritol triacrylate; PEI-HA: Poly(ethylenimine)-hyaluronic acid; PVP: polyvinylpyrrolidone; PEG-g-CHN: poly(ethylene glycol)-g-Chitosan; PEG-PLA: poly(ethylene glycol)-poly(lactic acid); PLLA: poly(l-lactic acid); HPCD: 2-hydroxypropyl-β-cyclodextrin; HA: Hyaluronic acid; MWCNT: multi-walled carbon nanotubes, PAA–Poly(acrylic acid); PECCL: poly(ethylene carbonate-ε-caprolactone); PDLLA: poly(d,l-lactic acid).